Business Information
The group's principal activity is to discover and development of small molecule drugs to treat major medical conditions including HIV, cancer and diabetes. The group's advanced product candidate, reverset(R), is a nucleoside analog reverse transcriptase inhibitor, or nrti, that is being developed as a once-a day oral therapy for use in combination with other antiviral drugs for patients with HIV infections. It also has four internally-generated drug discovery programs underway. The most advanced of these programs is focused on developing antagonists to a key receptor involved in inflammation called the ccr2 receptor. The registered trademarks are incyte, lifeseq, zooseq and bioknowledge. The group operates in the United States and in Austria, Belgium, Canada, France, Denmark, Germany, Israel, Japan, the Netherlands, Sweden, Switzerland, and the United Kingdom. On 19-Feb-2003, the group acquired maxia pharmaceuticals inc.
|
|
Name |
Title
|
Email
|
| Richard De Schutter | Chmn. | N/A | | Paul Friedman | Dir., CEO, Pres. | N/A | | Brian Metcalf | Exec. VP, Chief Drug Discovery Scientist | N/A | | David Hastings | CFO, Exec. VP | N/A | | John Keller | Exec. VP, Chief Business Officer | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 27,643 | (74,166) | | 2005 | 7,846 | (103,043) | | 2004 | 14,146 | (164,817)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
